Patents by Inventor Igor Beletsky

Igor Beletsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of determining the level of human TBP-II with anti-TBP-II antibody
    Patent number: 7455977
    Abstract: Antibodies to tumor necrosis factor receptors (TNF-Rs) are disclosed together with methods of producing them and methods of use of such antibodies in immunoassays and purification of TBP-II by affinity chromatography. A diagnostic assay for endogenous antibodies to TBP-II is also disclosed.
    Type: Grant
    Filed: August 4, 2003
    Date of Patent: November 25, 2008
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: David Wallach, Jacek Bigda, Igor Beletsky, Igor Mett, Hartmut Engelmann
  • TNF binding ligands and antibodies
    Publication number: 20040161858
    Abstract: Antibodies to tumor necrosis factor receptors (TNF-Rs) are disclosed together with methods of producing them and methods of use of such antibodies in immunoassays and purification of TBP-II by affinity chromatography. A diagnostic assay for endogenous antibodies to TBP-II is also disclosed.
    Type: Application
    Filed: August 4, 2003
    Publication date: August 19, 2004
    Applicant: Yeda Research and Development Co., Ltd.
    Inventors: David Wallach, Jacek Bigda, Igor Beletsky, Igor Mett, Hartmut Engelmann
  • TNF receptor-specific antibodies
    Publication number: 20030228312
    Abstract: Antibodies to Tumor Necrosis Factor receptors (TNF-Rs) which inhibit the cytocidal effect of TNF but not its binding to the TNF-Rs, and ligands interacting with other receptors of the TNF/NGF family, are provided together with methods of producing them. The antibodies preferably bind to the fourth cysteine rich domain of the p75 TNF receptor or to the region between said fourth cysteine rich domain and the cell membrane.
    Type: Application
    Filed: April 28, 2003
    Publication date: December 11, 2003
    Applicant: Yeda Research and Development Co. Ltd
    Inventors: David Wallach, Jacek Bigda, Igor Beletsky, Igor Mett, Hartmut Engelmann
  • DNA molecule encoding TNF binding ligands and vectors and host cells containing the DNA molecule
    Patent number: 6602993
    Abstract: DNA encoding Antibodies to tumor necrosis factor receptors (TNF-Rs) are disclosed. The antibodies are preferably those which inhibit the cytotoxic effect of TNF but not its binding to the TNF-Rs. Most preferably, the antibodies bind to an extracellular domain of the C-terminal cysteine loop of the p75 TNF receptor, which loop consists of the amino acid sequence Cys-185 to Thr-201 of SEQ ID NO:3.
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: August 5, 2003
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: David Wallach, Jacek Bigda, Igor Beletsky, Igor Mett, Hartmut Engelmann
  • Method of inhibiting the cytocidal effect of TNF with TNF receptor-specific antibodies
    Patent number: 6555111
    Abstract: Antibodies to Tumor Necrosis Factor receptors (TNF-Rs) which inhibit the cytocidal effect of TNF but not its binding to the TNF-Rs, and ligands interacting with other receptors of the TNF/NGF family, are provided together with methods of producing them. The antibodies preferably bind to the fourth cysteine rich domain of the p75 TNF receptor or to the region between said fourth cysteine rich domain and the cell membrane.
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: April 29, 2003
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: David Wallach, Jacek Bigda, Igor Beletsky, Igor Mett, Hartmut Engelmann
  • TNF binding ligands and antibodies
    Publication number: 20020111462
    Abstract: Antibodies to tumor necrosis factor receptors (TNF-Rs) are disclosed together with methods of producing them. The antibodies are preferably those which inhibit the cytotoxic effect of TNF but not its binding to the TNF-Rs. Most preferably, the antibodies bind to an extracellular domain of the C-terminal cysteine loop of the p75 TNF receptor, which loop consists of the amino acid sequence Cys-185 to Thr-201 of SEQ ID NO:3.
    Type: Application
    Filed: March 8, 2001
    Publication date: August 15, 2002
    Applicant: Yeda Research and Development Co., Ltd.
    Inventors: David Wallach, Jacek Bigda, Igor Beletsky, Igor Mett, Hartmut Engelmann
  • TNF receptor-specific antibodies
    Publication number: 20010019833
    Abstract: Antibodies to Tumor Necrosis Factor receptors (TNF-Rs) which inhibit the cytocidal effect of TNF but not its binding to the TNF-Rs, and ligands interacting with other receptors of the TNF/NGF family, are provided together with methods of producing them. The antibodies preferably bind to the fourth cysteine rich domain of the p75 TNF receptor or to the region between said fourth cysteine rich domain and the cell membrane.
    Type: Application
    Filed: March 8, 2001
    Publication date: September 6, 2001
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: David Wallach, Jacek Bigda, Igor Beletsky, Igor Mett, Hartmut Engelmann
  • TNF receptor-specific antibodies
    Patent number: 6262239
    Abstract: Antibodies to Tumor Necrosis Factor receptors (TNF-Rs) which inhibit the cytocidal effect of TNF but not its binding to the TNF-Rs, and ligands interacting with other receptors of the TNF/NGF family, are provided together with methods of producing them. The antibodies preferably bind to the fourth cysteine rich domain of the p75 TNF receptor or to the region between said fourth cysteine rich domain and the cell membrane.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 17, 2001
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: David Wallach, Jacek Bigda, Igor Beletsky, Igor Mett, Hartmut Engelmann
  • TNF ligands
    Patent number: 6232446
    Abstract: Antibodies to tumor necrosis factor receptors (TNF-Rs) are disclosed together with methods of producing them. The antibodies are preferably those which inhibit the cytotoxic effect of TNF but not its binding to the TNF-Rs. Most preferably, the antibodies bind to an extracellular domain of the C-terminal cysteine loop of the p75 TNF receptor, which loop consists of the amino acid sequence Cys-185 to Thr-201 of SEQ ID NO:3.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 15, 2001
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: David Wallach, Jacek Bigda, Igor Beletsky, Igor Mett, Hartmut Engelmann